chemical structure of tirzepatide (LY3298176) sodium | GIP/GLP-1 Receptor Agonist | CAS 2023788-19-2 (free base) Tirzepatide (5-39) CAS#: N/A •

The most common side effects are gastrointestinal (digestive), including: Nausea is the most commonly reported side effect, especially during the first few weeks after starting a GLP-1 medication

By addressing inflammation, pain processing, and metabolic health, they may offer benefits for some individuals further research is needed

For the right patient, prepared properly for the morning routine, it offers injection-comparable weight loss in a form many will find easier to accept

This direct-access model means your HSA and FSA funds work the same way whether you have employer coverage, self-funded an HSA, or are part of a spousal plan